Zilucoplan May Decrease Symptoms of Myasthenia Gravis

Share this post

The novel self-administered subcutaneous agent is safe and relatively well tolerated in generalized myasthenia gravis, a new phase 2 trial and extension study report.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply